Health Care & Life Sciences » Pharmaceuticals | Kadmon Holdings Inc.

Kadmon Holdings Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
64,356.00
147,082.00
208,755.00
83,610.00
54,252
Depreciation, Depletion & Amortization
24,448.00
29,754.00
17,503.00
1,822.00
1,534
Other Funds
27,897.00
66,902.00
140,120.00
25,592.00
23,238
Funds from Operations
12,040.00
50,429.00
51,105.00
56,633.00
76,480
Changes in Working Capital
3,951.00
10,904.00
1,845.00
7,465.00
4,657
Net Operating Cash Flow
15,991.00
61,333.00
52,950.00
64,098.00
71,823
Capital Expenditures
2,062.00
161.00
539.00
479.00
Net Investing Cash Flow
2,062.00
161.00
539.00
479.00
Issuance/Reduction of Debt, Net
40,114.00
36,227.00
3,914.00
20.00
Net Financing Cash Flow
1,241.00
62,090.00
68,084.00
96,001.00
Net Change in Cash
19,294.00
596.00
14,595.00
31,424.00
Free Cash Flow
18,053.00
61,494.00
53,489.00
64,577.00
Deferred Taxes & Investment Tax Credit
29.00
3.00
27.00
437.00
524
Change in Capital Stock
38,873.00
25,863.00
71,998.00
96,021.00

About Kadmon Holdings

View Profile
Address
450 East 29th Street
New York New York 10016
United States
Employees -
Website http://www.kadmon.com
Updated 07/08/2019
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. Its products include Ribasphere RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.